NDAINJECTIONINJECTABLE
Approved
Jun 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
17
Data completeness
3/8 — Basic
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIBATIV (telavancin) is a lipoglycopeptide antibiotic approved in 2013 for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible pathogens. It is administered intravenously and represents an alternative to vancomycin for serious gram-positive respiratory infections. Telavancin's enhanced cell wall penetration makes it effective against multidrug-resistant organisms.
$0.78MPart D
PeakProduct is at peak lifecycle stage with modest Part D claims (~200 annually), indicating limited market penetration in the hospital antibiotic space where Medicare outpatient data is minimal.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (17)
Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage
Started Jul 2024
20 enrolled
Subarachnoid Hemorrhage, Aneurysmal
Telavancin Pharmacokinetics in Cystic Fibrosis Patients
Started Aug 2017
18 enrolled
Cystic Fibrosis
Pharmacokinetics of Telavancin in Normal and Obese Subjects
Started Apr 2016
32 enrolled
Healthy
Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5
Started Jul 2015
8 enrolled
End-Stage Renal DiseaseStage 5 Chronic Kidney Disease
Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)
Started Dec 2014
22 enrolled
Gram-Positive Bacterial Infections
Worked on VIBATIV at Theravance Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.